Alnylam Pharma (ALNY) Tops Q1 EPS by 65c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at BMO Capital
May 1, 2019 12:59 PM EDTBMO Capital analyst Do Kim raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $128.00 (from $126.00) while maintaining a Outperform rating following Q1 results.
The analyst commented, "We raise our Onpattro projections and target price to $128 from $126, as 1Q19 sales beat our and... More
